Cetilistat is a novel, orally active gastrointestinal and pancreatic lipase inhibitor developed for the treatment of obesity and related metabolic conditions. By blocking the breakdown and absorption of dietary fat, Cetilistat offers an effective and well-tolerated approach to weight loss, making it a valuable ingredient in modern anti-obesity therapies.

Key Features:

• Effective Fat Absorption Blocker: Inhibits lipase activity in the gastrointestinal tract, reducing calorie intake from fat.

• Weight Management: Promotes meaningful weight loss when combined with a reduced-calorie diet.

• Improves Metabolic Markers: Supports better control of obesity-related conditions such as type 2 diabetes, dyslipidemia, and hypertension.

• Better Tolerability: Compared to similar agents like Orlistat, Cetilistat has shown improved gastrointestinal tolerability.

Applications:

• Obesity Treatment Formulations

• Metabolic Syndrome Research

• Weight Loss Supplement Development

• Pharmaceutical R&D